Table 2.

Clinical outcomes in propensity score matched group

Variable	Total (N = 378)	Use of regdanvimab (N = 189)	No use of regdanvimab (N = 189)	p value
Use of oxygen therapies	45 (11.9%)	14 (7.4%)	31 (16.4%)	0.007
Use of high flow nasal cannula	19 (5.0%)	5 (2.6%)	14 (7.4%)	0.034
Use of mechanical ventilation	2 (0.5%)	1 (0.5%)	1 (0.5%)	1
Use of intensive care units	20 (5.3%)	8 (4.2%)	12 (6.3%)	0.358
Worst severity during hospitalization				< 0.001
Asymptomatic	2 (0.5%)	2 (1.1%)	0 (0.0%)
Mild	211 (55.8%)	88 (46.6%)	123 (65.1%)
Moderate	116 (30.7%)	81 (42.9%)	35 (18.5%)
Severe	41 (10.8%)	17 (9.0%)	24 (12.7%)
Critical	8 (2.1%)	1 (0.5%)	7 (3.7%)
Mortality	7 (1.9%)	1 (0.5%)	6 (3.2%)	0.122
30-Day mortality	6 (1.6%)	0 (0.0%)	6 (3.2%)	0.030
Severe/critical or mortality	49 (13.0%)	18 (9.5%)	31 (16.4%)	0.047
Use of additional therapeutic agents
Remdesivir	34 (9.0%)	13 (6.9%)	21 (11.1%)	0.150
Dexamethasone	42 (11.1%)	16 (8.5%)	26 (13.8%)	0.102